Crux Biomedical receives financial influx

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Hercules Technology Growth Capital, a finance company, has provided a $250,000 direct equity investment to Crux Biomedical, a medical device firm developing an inferior vena cava (IVC) filter for the treatment and prevention of pulmonary embolism.

“The equity from Hercules will support our pivotal U.S. clinical trials and pioneering research and development efforts,” said Mel Schatz, CEO of Crux. “We expect to achieve a leadership position in this growing field by providing the easiest, most versatile IVC filter.”

In addition to Hercules’ equity investment, the Palo Alto, Calif.-based Crux has also received equity from Thomas Fogarty and Alloy Ventures.